May 2015 (Medical News Today)
A course of new antiviral drugs in a clinical trial has resulted in almost all the patients with chronic hepatitis C infection becoming virus-free, even those whose disease meant they had scarring of the liver and so were at transplant or cancer risk.
The results of the two trials of the drugs used in combination – daclatasvir, asunaprevir and beclabuvir – are published online by JAMA.
Overall, the authors conclude, SVR12 was achieved by 93% of 202 patients with genotype 1 infection and compensated cirrhosis after 12 weeks of treatment with the fixed-dose combination of daclatasvir, asunaprevir, and beclabuvir, with or without Ribavirin.